Chemistry:Ensituximab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | MUC5AC |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6342H9800N1678O1985S46 |
| Molar mass | 142788.68 g·mol−1 |
  (what is this?) (verify) | |
Ensituximab (NPC-1C) is a chimeric monoclonal antibody under development for as a candidate for treatment of cancers.[1] The target of the antibody is uncertain and is described as "human colorectal and pancreatic carcinoma-associated antigens", a set of tumor antigens isolated from human cancers.[2] The target might be Mucin 5AC.[3]
The antibody was discovered by scientists at Neogenix Oncology using tumor antigens that had been identified years earlier by Ariel Hollinshead; the founder of Neogenix had founded a prior company based on Hollinshead's work as well.[4] Neogenix worked with Selexis to develop the CHO cell line expressing ensituximab[5][6] and also worked with Goodwin Biotechnology Inc on process development.[7]
Ensituximab was granted orphan drug designation for pancreatic cancer by the FDA in 2010.[8]
In 2011 Neogenix was forced to declare bankruptcy because the SEC opened an investigation into its use of unregistered broker-dealers in the course of raising $30M, and it could not raise further funds; in 2012 Neogenix sold its assets to a group of its investors who had formed a company called Precision Biologics.[9]
In 2016, Precision released data from a Phase II trial colorectal cancer and at that time was working with Cytovance Biologics as its contract manufacturing organization.[10]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/ensituximab.pdf.
- ↑ "Ensituximab" (in en). NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436.
- ↑ "Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer". Clinical Cancer Research 26 (14): 3557–3564. 2020. doi:10.1158/1078-0432.CCR-20-0426. ISSN 1078-0432. PMID 32303539.
- ↑ Morrison, Trista (July 11, 2007). "Neogenix Uses Cancer Vaccine And Antibody Approaches". BioWorld Today. http://www.bioworld.com/content/newco-news-neogenix-uses-cancer-vaccine-and-antibody-approaches.
- ↑ Neogenix Oncology, Inc. - Pharmaceuticals & healthcare - Deals and alliances profile. (2015). London: Global Data Ltd.
- ↑ "Press ReleaseL Selexis and Neogenix Oncology Execute Commercial License Agreement - Selexis SA". Selexis SA. 5 January 2011. http://www.selexis.com/selexis-neogenix-oncology-execute-commercial-license-agreement/.
- ↑ "From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics". Frost & Sullivan. 14 September 2007. http://www.growthconsulting.frost.com/web/images.nsf/0/DFB3A440F8FFB11C65257363001AC49E/$File/TI%20Alert.htm.
- ↑ Staff (1 December 2010). "FDA Pipeline Preview, December 2010 (Ezogabine, Solesta, Dutasteride, Finasteride, Octaplex, SF1126, MP4CO, Ensituximab, Naloxone, CBLB502)" (in en). Formulary Journal. http://formularyjournal.modernmedicine.com/formulary-journal/news/clinical/clinical-pharmacology/fda-pipeline-preview-december-2010-ezogabine-s.
- ↑ Davie, Alexander J. (5 October 2012). "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 1: How It All Happened". Strictly Business. https://www.strictlybusinesslawblog.com/2012/10/05/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-1-how-it-all-happened/.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 2: What Neogenix Did". Strictly Business. 24 October 2012. https://www.strictlybusinesslawblog.com/2012/10/24/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-2-what-neogenix-did/.. "Neogenix Oncology: A Good Case Study on Securities Law (Non)Compliance by a High Growth Company – Part 3: When the Genie Can't Be Put Back in the Bottle". Strictly Business. 17 November 2012. https://www.strictlybusinesslawblog.com/2012/11/16/neogenix-oncology-a-good-case-study-on-securities-law-noncompliance-by-a-high-growth-company-part-3-when-the-genie-cant-be-put-back-in-the-bottle/.
- ↑ "Ensituximab - Precision Biologics". Adis Insight. Springer Nature Switzerland AG. http://adisinsight.springer.com/drugs/800031614.
 |  |
